Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab with carboplatin and etoposide within its marketing authorisation for untreated extensive-stage small-cell lung cancer
 
Status In progress
Process STA 2018
ID number 1504

Provisional Schedule

Expected publication 11 December 2019

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Roche Products (atezolizumab)
  Roy Castle Lung Cancer Foundation
  Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) (confidentiality form not signed, not participating)
  Bristol-Myers Squibb Pharmaceuticals limited (etoposide) (confidentiality form not signed, not participating)
  Hospira UK (cisplatin, carboplatin, gemcitabine, irinotecan) (confidentiality form not signed, not participating)
  Lilly UK (gemcitabine) (confidentiality form not signed, not participating)
  Medac GmbH (etoposide, gemcitabine, irinotecan) (confidentiality form not signed, not participating)
  Pfizer (carboplatin, cisplatin, gemcitabine, irinotecan) (confidentiality form not signed, not participating)
  Sandoz (cisplatin) (confidentiality form not signed, not participating)
  Seacross Pharmaceuticals Ltd (irinotecan) (confidentiality form not signed, not participating)
  Shire Pharmaceuticals Ltd (irinotecan) (confidentiality form not signed, not participating)
  Sun Pharma (gemcitabine) (confidentiality form not signed, not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Network

Timeline

Key events during the development of the guidance:

Date Update
02 October 2019 Committee meeting: 1
07 December 2018 Invitation to participate
16 October 2018 - 13 November 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
13 February 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance